CLDN6 and endometrial cancer: We have recently reported that aberrant CLDN6 expression in endometrial cancer tissues is significantly associated with several clinicopathological variables, such as surgical stage III/IV, histological type, histological grade 3, lymphovascular space involvement, lymph node metastasis, and distant metastasis.82 Additionally, we showed that the high CLDN6 expression in endometrial cancer represents an independent prognosis marker, and the 5-y survival rate was approximately 30%, which was one-third of that in the low-expression group.